Log in
NASDAQ:HGEN

Humanigen Stock Forecast, Price & News

$12.96
-0.71 (-5.20 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$12.88
Now: $12.96
$13.42
50-Day Range N/A
52-Week Range
$1.50
Now: $12.96
$33.95
Volume380,373 shs
Average Volume179,389 shs
Market Capitalization$650.19 million
P/E RatioN/A
Dividend YieldN/A
Beta-2.14
Humanigen, Inc., a biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase I/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. The company has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase I/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a partnership with Catalent Biologics to manufacture investigational covid-19 therapeutic candidate Lenzilumab. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.79 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HGEN
CUSIPN/A
CIKN/A
Phone650 243 3100
Employees2

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.63) per share

Profitability

Net Income$-10,290,000.00

Miscellaneous

Market Cap$650.19 million
Next Earnings Date10/26/2020 (Estimated)
OptionableOptionable
$12.96
-0.71 (-5.20 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for HGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Humanigen (NASDAQ:HGEN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Humanigen?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humanigen in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Humanigen
.

When is Humanigen's next earnings date?

Humanigen is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020.
View our earnings forecast for Humanigen
.

How were Humanigen's earnings last quarter?

Humanigen, Inc. (NASDAQ:HGEN) released its quarterly earnings results on Friday, August, 14th. The company reported ($0.80) earnings per share (EPS) for the quarter.
View Humanigen's earnings history
.

What price target have analysts set for HGEN?

3 brokers have issued 1-year price targets for Humanigen's shares. Their forecasts range from $25.00 to $31.00. On average, they expect Humanigen's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 116.1% from the stock's current price.
View analysts' price targets for Humanigen
.

Who are some of Humanigen's key competitors?

Who are Humanigen's key executives?

Humanigen's management team includes the following people:
  • Dr. Cameron Durrant M.B.A., M.D., MBA, Chairman & CEO (Age 60, Pay $784.5k)
  • Mr. Timothy Morris CPA, CPA, CFO & COO (Age 58, Pay $66k)
  • Mr. David L. Tousley CPA, M.B.A., CPA, Chief Accounting & Admin. Officer, Corp. Sec. and Treasurer (Age 64)
  • Dr. Dale Chappell M.B.A., M.D., MBA, Chief Scientific Officer (Age 50)
  • Dr. Tarek Sahmoud, Chief Medical Officer

What is Humanigen's stock symbol?

Humanigen trades on the NASDAQ under the ticker symbol "HGEN."

How do I buy shares of Humanigen?

Shares of HGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Humanigen's stock price today?

One share of HGEN stock can currently be purchased for approximately $12.96.

How big of a company is Humanigen?

Humanigen has a market capitalization of $650.19 million. Humanigen employs 2 workers across the globe.

What is Humanigen's official website?

The official website for Humanigen is www.humanigen.com.

How can I contact Humanigen?

Humanigen's mailing address is 533 Airport Boulevard Ste. 400, Burlingame CA, 94010. The company can be reached via phone at 650 243 3100 or via email at [email protected]

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.